Arevir: a secure platform for designing personalized antiretroviral therapies against HIV

Authors:
Kirsten Roomp;Niko Beerenwinkel;Tobias Sing;Eugen Schülter;Joachim Büch;Saleta Sierra-Aragon;Martin Däumer;Daniel Hoffmann;Rolf Kaiser;Thomas Lengauer;Joachim Selbig
Affiliations:
Max Planck Institute for Informatics, Saarbrücken, Germany;Department of Mathematics, University of California, Berkeley;Max Planck Institute for Informatics, Saarbrücken, Germany;Center of Advanced European Studies and Research (caesar), Bonn, Germany;Max Planck Institute for Informatics, Saarbrücken, Germany;Institute of Virology, University of Cologne, Köln, Germany;Institute of Virology, University of Cologne, Köln, Germany;Center of Advanced European Studies and Research (caesar), Bonn, Germany;Institute of Virology, University of Cologne, Köln, Germany;Max Planck Institute for Informatics, Saarbrücken, Germany;University of Potsdam and Max Planck Institute for Molecular Plant Physiology, Golm-Potsdam, Germany
Venue:
DILS'06 Proceedings of the Third international conference on Data Integration in the Life Sciences
Year:
2006

Citing 4
Cited 2

A method for obtaining digital signatures and public-key cryptosystems

Communications of the ACM
Geno2pheno: Interpreting Genotypic HIV Drug Resistance Tests

IEEE Intelligent Systems
ROCR: visualizing classifier performance in R

Bioinformatics
Computational methods for the design of effective therapies against drug resistant HIV strains

Bioinformatics

HIV-1 Drug Resistance Prediction and Therapy Optimization: A Case Study for the Application of Classification and Clustering Methods

Similarity-Based Clustering
Chasing the AIDS virus

Communications of the ACM

Quantified Score

Hi-index	0.02

Visualization

Abstract

Despite the availability of antiretroviral combination therapies, success in drug treatment of HIV-infected patients is limited. One reason for therapy failure is the development of drug-resistant genetic variants. In principle, the viral genomic sequence provides resistance information and could thus guide the selection of an optimal drug combination. In practice however, the benefit of this procedure is impaired by (1) the difficulty in inferring the clinically relevant information from the genotype of the virus and (2) the restricted availability of this information. We have developed a secure platform for collaborative research aimed at optimizing anti-HIV therapies, called Arevir. A relational database schema was designed and implemented together with a web-based user interface. Our system provides a basis for monitoring patients, decision-support, and computational analyses. Thus, it merges clinical, diagnostic and bioinformatics efforts to exploit genomic and patient therapy data in clinical practice.